Literature DB >> 20470777

Eradication of Taenia solium cysticercosis: a role for vaccination of pigs.

Marshall W Lightowlers1.   

Abstract

Taenia solium is the causative agent of neurocysticercosis, a disease responsible for substantial human morbidity and mortality. It is a zoonotic parasite, involving pigs as intermediate hosts. The parasite's full life cycle is restricted to poor people in developing countries. Attempts to date to control transmission of the parasite have been relatively poorly effective and not sustainable. Over the past decade research has been undertaken to develop practical vaccines for use in pigs to prevent transmission of T. solium. The most effective of these vaccines in controlled experimental trials has been the TSOL18 vaccine. More recently, TSOL18 has been proven to be highly effective against naturally acquired infection with T. solium in pigs. Application of TSOL18 together with a single treatment of pigs with oxfendazole achieved the complete elimination of transmission of the parasite by pigs involved in the field trial. This strategy may provide a relatively low cost and sustainable control tool which could assist towards the goal of achieving eradication of the parasite. An assessment is made of the potential value of various control measures that are available for T. solium, and two options are suggested as potential parasite control programs. Copyright 2010 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470777     DOI: 10.1016/j.ijpara.2010.05.001

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  34 in total

1.  Vaccines and future global health needs.

Authors:  G J V Nossal
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 2.  Prevention and control of Taenia solium taeniasis/cysticercosis in Peru.

Authors:  Robert H Gilman; Armando E Gonzalez; Fernando Llanos-Zavalaga; Victor C W Tsang; Hector H Garcia
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

Review 3.  Hydrocephalus in neurocysticercosis.

Authors:  Hamilton Matushita; Fernando Campos Gomes Pinto; Daniel Dante Cardeal; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

Review 4.  Vaccines to combat the neglected tropical diseases.

Authors:  Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Strategies for optimal expression of vaccine antigens from Taeniid cestode parasites in Escherichia coli.

Authors:  Charles Gauci; David Jenkins; Marshall W Lightowlers
Journal:  Mol Biotechnol       Date:  2011-07       Impact factor: 2.695

6.  Neurocysticercosis in immigrant populations.

Authors:  Hector H Garcia
Journal:  J Travel Med       Date:  2012 Mar-Apr       Impact factor: 8.490

7.  Neurocysticercosis.

Authors:  Pratibha Singhi
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

8.  Characterization of a novel cathepsin L-like protease from Taenia solium metacestodes for the immunodiagnosis of porcine cysticercosis.

Authors:  Nancy León-Janampa; Ruddy Liendo; Robert H Gilman; Carlos Padilla; Hector H García; Armando Gonzales; Patricia Sheen; Mónica J Pajuelo; Mirko Zimic
Journal:  Vet Parasitol       Date:  2019-01-29       Impact factor: 2.738

9.  Taenia solium taeniasis and cysticercosis control and elimination through community-based interventions.

Authors:  Hélène Carabin; Aminata A Traoré
Journal:  Curr Trop Med Rep       Date:  2014-12-01

10.  Genes encoding homologous antigens in taeniid cestode parasites: Implications for development of recombinant vaccines produced in Escherichia coli.

Authors:  Charles Gauci; Marshall W Lightowlers
Journal:  Bioengineered       Date:  2012-05-01       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.